Helvetic Biopharma

Company snapshot

Helvetic Biopharma is an innovative bio-pharmaceutical company based in Ticino, Switzerland. The technology platform we apply includes the manufacturing of recombinant proteins and monoclonal antibodies for therapeutic use. The therapeutic areas in which we are involved are, among the others, Oncology, Hematology, Immuno-modulation and Auto-immune diseases cure.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Helvetic Biopharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Helvetic Biopharma.

1. Jun 8, 2026 Clinical update

   NEPA-23-01 — Phase 1

View all clinical trial activity →

• What is Helvetic Biopharma?

  Helsinn Birex Pharmaceuticals is a pharma organization headquartered in Dublin, IE. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1).

• Is Helvetic Biopharma publicly traded?

  Helvetic Biopharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Helvetic Biopharma develop or market?

  We link 10 drug profile(s) where Helvetic Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/helsinn-birex-pharmaceuticals#company-drugs.

• What are the latest developments for Helvetic Biopharma?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Helvetic Biopharma focus on?

  No specific therapeutic focus areas are currently identified for Helvetic Biopharma in our database.